| Followers | 33 |
| Posts | 3040 |
| Boards Moderated | 0 |
| Alias Born | 01/26/2011 |
Thursday, July 07, 2022 2:46:37 PM
"If that’s what you wish to label long-term investing,..."
The original premise was that you would not sell any of your AVXL holdings today for $2000 per share.
I consider myself a minute-trader, day-trader, swing trader, position trader, short-term investor and long-term investor. Heck, at times (like with AVXL for instance) I am all of those things with one stock! I have held AVXL shares for as little as a few minutes and as long as 7 years and counting. I have strictly day-traded many stocks over the years and have also held onto one particular stock for nearly 45 years...
Going back to your original premise above, my response to it had nothing to do with labeling what type of investing it is. I was simply stating that I personally do not believe anyone would be able to turn down an offer today that would result in him or her gaining in excess of 186x the current value of his or hers holding (being paid $2,000,000 today for every 1,000 shares that are currently worth under $13,000). Since of course an offer like this will never happen, I hope this ride will eventually take us into 4-digit land. If you are truly able to keep yourself from selling any of your shares until that price becomes reality, I promise I will be the first to tip my cap to you (and to anyone else here who is able to do that as well)!
The original premise was that you would not sell any of your AVXL holdings today for $2000 per share.
I consider myself a minute-trader, day-trader, swing trader, position trader, short-term investor and long-term investor. Heck, at times (like with AVXL for instance) I am all of those things with one stock! I have held AVXL shares for as little as a few minutes and as long as 7 years and counting. I have strictly day-traded many stocks over the years and have also held onto one particular stock for nearly 45 years...
Going back to your original premise above, my response to it had nothing to do with labeling what type of investing it is. I was simply stating that I personally do not believe anyone would be able to turn down an offer today that would result in him or her gaining in excess of 186x the current value of his or hers holding (being paid $2,000,000 today for every 1,000 shares that are currently worth under $13,000). Since of course an offer like this will never happen, I hope this ride will eventually take us into 4-digit land. If you are truly able to keep yourself from selling any of your shares until that price becomes reality, I promise I will be the first to tip my cap to you (and to anyone else here who is able to do that as well)!
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
